Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,433 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06784752RecruitingPhase 3
Testing a targeted radiation therapy for advanced neuroendocrine tumors
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Scottsdale, ArizonaAges 12–100 - NCT06786052RecruitingPhase 2
Study on after-meal energy in adults 50–70
This trial studies how a probiotic supplement affects energy use after meals in adults aged 50–70 who are overweight. You'll take either the probiotic or a placebo for several weeks.
Pierre-Bénite, Auvergne-Rhône-AlpesAges 50–70 - NCT06792253RecruitingPhase 3
BEBT-908 plus rituximab for relapsed large B-cell lymphoma
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
Beijing, Beijing MunicipalityAges 18–75 - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Gilbert, ArizonaAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06788717Enrolling by invitation
Study on Hip Revision Stem Performance
This study is checking how well a specific hip implant (the Comprehensive Revision Stem) works in people who need hip replacement. It helps make sure the implant is safe and effective over time.
Los Angeles, CaliforniaAges 18–100 - NCT06783114RecruitingPhase 2/Phase 3
Testing a new Botox-like injection for arm stiffness after stroke
This study tests an investigational botulinum toxin injection (YY001) to reduce muscle stiffness in the arm after a stroke. It may help you move your arm more easily and improve daily tasks.
Hefei, AnhuiAges 18–75 - NCT06789406Recruiting
Testing a new sacral nerve stimulation device for overactive bladder
This study tests a new version of a sacral nerve stimulation device (Axonics model 5101) for people with overactive bladder. It aims to see if the device is safe and works well to reduce sudden urges and frequent urination.
Chicago, IllinoisAges 18 years+ - NCT06784466Recruiting
New ablation procedure for atrial fibrillation
This study is testing a new type of ablation procedure for atrial fibrillation (an irregular heart rhythm). It uses special energy to create scar tissue in the heart to block faulty electrical signals. If you have AF that isn’t controlled by medication, you may qualify.
Birmingham, AlabamaAges 18–80 - NCT06792019RecruitingPhase 1/Phase 2
Study of CM313 injection for platelet transfusion resistance
This trial tests a new drug called CM313 to see if it can help people whose platelet transfusions stop working. It is for adults who need platelet transfusions and have developed antibodies against them.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06783569RecruitingPhase 1
First-in-human study for advanced solid tumors
This trial tests a new experimental drug for people with advanced solid tumors that have not responded to standard treatments. It aims to find a safe dose and see if the drug can shrink tumors.
Harbin, Heiljiang ProvinceAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT06782490RecruitingPhase 2
Testing a new drug for MS muscle stiffness
This study tests an investigational drug (BMS-986368) to see if it helps reduce muscle stiffness and spasms caused by multiple sclerosis. It may be an option if you have had spasticity for at least 6 months and are not currently using other treatments that cannot be paused.
Birmingham, AlabamaAges 18–70 - NCT06789861RecruitingPhase 1
First test of TT5 in healthy volunteers and surgical patients
This is a first-in-human study testing a new medicine (TT5) in healthy people and patients recovering from surgery. It checks how the body handles the drug and whether it is safe to use for pain.
Adelaide, South AustraliaAges 18–55 - NCT04686253Recruiting
Study how a heart opening and its flow link to stroke
This study looks at the detailed flow pattern through a patent foramen ovale (PFO)—a small opening in the heart—and how it may relate to stroke, TIA, or migraine. Doctors use special ultrasound testing with contrast to better understand who is most affected.
Beijing, Beijing MunicipalityAges 16–65 - NCT03772561RecruitingPhase 1
Testing AZD5363, olaparib, and durvalumab for advanced solid cancers
This Phase 1 trial tests a combination of three medicines to shrink or control advanced solid tumors that are progressing or no standard options exist. It mainly focuses on safety and early signs of how well the treatment works.
Singapore, SingaporeAges 21–99 - NCT03358693Recruiting
Study of inflammation patterns in chronic skin diseases
This study looks at molecular (body-level) signatures in people with chronic inflammatory skin conditions. You may help researchers understand what drives inflammation, while receiving standard (already approved) systemic treatment through routine care.
KielAges Any age - NCT03361215Recruiting
Tracking skin disease patterns and anti-inflammatory response
This study looks at how atopic dermatitis (eczema), psoriasis, or other autoimmune skin diseases change over time and how the body responds to anti-inflammatory signals. Your information and—if eligible—samples help researchers find patterns that could guide better treatments.
KielAges birth–100 years - NCT05701709RecruitingPhase 1
First-in-human test for a new drug in advanced solid cancers
This Phase 1 study tests SHR-A2102, a new cancer medicine, in adults with advanced solid tumors. It mainly looks at safety and how the body handles the drug, and it may help if standard treatments are not working or are not an option.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06049082RecruitingPhase 1
A study of KB408 for alpha-1 antitrypsin deficiency
This study tests a new gene therapy called KB408 for people with alpha-1 antitrypsin deficiency (AATD). It aims to see if KB408 can help your body produce enough of the missing protein to protect your lungs and liver.
Gainesville, FloridaAges 18–70 - NCT06679244Recruiting
New surgery for upper stomach cancer
This trial tests a new surgical technique for patients with cancer in the upper part of the stomach or where the stomach meets the esophagus. It aims to see if the new approach is safe and effective for removing the tumor and nearby lymph nodes.
ShanghaiAges 18–80 - NCT06787261Recruiting
Study of oral microbes linked to cavities
This study looks for tiny organisms called archaea in the mouth and how they might be related to cavities. It may help us learn more about what causes tooth decay.
MarseilleAges 18 years+ - NCT06789003Recruiting
Prehabilitation with exercise for multiple myeloma patients
This trial tests whether a prehabilitation program using adapted physical activity can help multiple myeloma patients prepare for a stem cell transplant. It may improve your strength and recovery before and after the transplant.
AvignonAges 18 years+
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,433 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.